Dated: September 23, 2025.

Rosalind M. Niamke,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2025–18691 Filed 9–25–25; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Center for Complementary & Integrative Health; Notice of Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Advisory Council for Complementary and Integrative Health.

The meeting will be held as a virtual meeting and will be open to the public as indicated below. Individuals who plan to view the virtual meeting and need special assistance or other reasonable accommodations to view the meeting, should notify the Contact Person listed below in advance of the meeting. Once available, the open session meeting link can be accessed at the Institute's/Center's home page: *https://nccih.nih.gov/about/naccih.*

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Advisory Council for Complementary and Integrative Health.

Date: January 23, 2026.

Closed: 10:00 a.m. to 12:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, DEM 2, Suite 401, 6707 Democracy Boulevard, Bethesda, MD 20892, Virtual Meeting.

Open: 12:30 p.m. to 5:00 p.m.

Agenda: Reports and Updates about Recent and Ongoing NCCIH Led or Involved Activities by NCCIH staff and its Director.

Address: National Institutes of Health, DEM 2, Suite 401, 6707 Democracy Boulevard, Bethesda, MD 20892, Virtual Meeting.

Contact Person: Martina Schmidt, Ph.D., Director, Division of Extramural Activities, National Center for Complementary & Integrative Health, NIH, 6707 Democracy Blvd., Suite 401, Bethesda, MD 20892, (301) 594–3456, *schmidma@mail.nih.gov.*

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should be less than 700 words in length, and should include the name, email address, telephone number and when applicable, the business or professional affiliation of the interested person. *Any member of the public may submit written comments no later than January 9th, 2026 (14 days before the council meeting).*

Information is also available on the Institute's/Center's home page: *https://nccih.nih.gov/about/naccih,* where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.213, Research and Training in Complementary and Alternative Medicine, National Institutes of Health, HHS)

Dated: September 24, 2025.

Bruce A. George,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2025–18720 Filed 9–25–25; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License, Inter-Institutional Agreement-Institution Lead: Development of Zika Virus Strains for Use in Oncolytic Therapy

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The National Institute of Allergy and Infectious Diseases, an institute of the National Institutes of Health, Department of Health and Human Services, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to Advocate Aurora Research Institute, located in Milwaukee, Wisconsin, to practice the inventions embodied in the patent applications listed in the Supplementary Information section of this notice.

DATES: Only written comments and/or applications for a license which are received by the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases on or before October 14, 2025 will be considered.

ADDRESSES: Requests for copies of the patent applications, inquiries, and comments relating to the contemplated exclusive patent license should be directed to: Elizabeth Pitts, Senior Technology Transfer and Patent Specialist, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Suite 2G, MSC9804, Rockville, MD 20852–9804, phone number 301–669–5299, or *Elizabeth.pitts@nih.gov.*

SUPPLEMENTARY INFORMATION: The following represents the intellectual property to be licensed under the prospective agreement: United States Provisional Patent Application Number 63/607,147, filed December 7, 2023, entitled ''Zika Viruses and Uses Thereof'' (HHS Reference No. E–137–2025–0–US–01) and PCT Patent Application Number PCT/US2024/058992, filed December 7, 2024, entitled ''Zika Viruses and Uses Thereof'' (HHS Reference No. E–137–2025–0–PCT–02).

The patent rights in these inventions have been assigned and/or exclusively licensed to Advocate Aurora Research Institute and Government of the United States of America as represented by the Secretary, Department of Health & Human Services.

The prospective patent license will be for the purpose of consolidating the patent rights to Advocate Aurora Research Institute, the co-owners of said rights, for commercial development and marketing. Consolidation of these co-owned rights is intended to expedite development of the invention, consistent with the goals of the Bayh-Dole Act codified as 35 U.S.C. 200–212.

The prospective interinstitutional agreement will include an exclusive license for the National Institute of Allergy and Infectious Diseases' rights in these jointly owned patents. It will be sublicensable, and any sublicenses granted by Advocate Aurora Research Institute will be subject to the provisions of 37 CFR part 404.

Glioblastoma multiforme (GBM) is an aggressive, malignant brain cancer with poor prognosis under the current standard of care. Oncolytic viruses have potential as novel therapeutics for the treatment of GBM. The current technology, developed by Stephen Whitehead, Ph.D. from the National Institute of Allergy and Infectious Diseases and researchers at Advocate Aurora Research Institute, describes the use of Zika virus strains as an oncolytic virus for the treatment of GBM and other cancers.

This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license will be royalty bearing, and the prospective exclusive license may be granted unless within fifteen (15) days from the date of this published notice, the National Insitute of Allergy and Infectious Diseases receives written evidence and argument that establishes that the grant

of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.

In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially, and may be made publicly available.

License applications submitted in response to this Notice will be presumed to contain business confidential information and any release of information in these license applications will be made only as required and upon a request under *the Freedom of Information Act,* 5 U.S.C. 552.

Dated: September 23, 2025.

Surekha Vathyam,

Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases.

[FR Doc. 2025–18692 Filed 9–25–25; 8:45 am]

BILLING CODE 4140–01–P

INTERNATIONAL TRADE COMMISSION

Notice of Receipt of Complaint; Solicitation of Comments Relating to the Public Interest

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

SUMMARY: Notice is hereby given that the U.S. International Trade Commission has received a complaint entitled *Certain Open-Ear Earpiece Devices, DN 3851;* the Commission is soliciting comments on any public interest issues raised by the complaint or complainant's filing pursuant to the Commission's Rules of Practice and Procedure.

FOR FURTHER INFORMATION CONTACT: Lisa R. Barton, Secretary to the Commission, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436, telephone (202) 205–2000. The public version of the complaint can be accessed on the Commission's Electronic Document Information System (EDIS) at *https://edis.usitc.gov.* For help accessing EDIS, please email *EDIS3Help@usitc.gov.*

General information concerning the Commission may also be obtained by accessing its internet server at United States International Trade Commission (USITC) at *https://www.usitc.gov* . The public record for this investigation may be viewed on the Commission's Electronic Document Information System (EDIS) at *https://edis.usitc.gov.* Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission's TDD terminal on (202) 205–1810.

SUPPLEMENTARY INFORMATION: The Commission has received a complaint and a submission pursuant to § 210.8(b) of the Commission's Rules of Practice and Procedure filed on behalf Bose Corporation on September 23, 2025. The complaint alleges violations of section 337 of the Tariff Act of 1930 (19 U.S.C. 1337) in the importation into the United States, the sale for importation, and the sale within the United States after importation of certain open-ear earpiece devices. The complaint names as respondents: Dongguan Yuanyu Electronic Co., Ltd. d/b/a Ituoray of China; Liu, Yiming d/b/a Yomdud of China; King Lucky Co., Ltd. of Hong Kong; Jiaxing Yuejia Trading Co., Ltd. d/b/a Xmenha of China; Shenzhen Zhichuang All Technology Co., Ltd. and/or Abbott Sanag (UK) Group Co., Ltd. d/b/a Sanag Lingzhong Zhao d/b/a Jzones of China; Shenzhen Mengmengwei Electronic Commerce Co., Ltd. d/b/a Lytmi of China; Shenzhen Maosong Tech. Co., Ltd., d/b/a Ansten of China; U2O Global Co., Ltd. d/b/a IWalk of China; Shenzhen Meichi Electronics Co., Ltd. d/b/a HOMSCAM of China; Shenzhen Shixinhe Dianzi Shangwu Co., Ltd. d/b/a XINHESHUMA of China; Shenzhen Landscape Art Co., Ltd. d/b/a Piluyaa of China; Shenzhen Zhiquhui Technology Co., Ltd. d/b/a Yeabomy of China; Shenzhen Carnival Digital Technology Co., Ltd. and/or Shenzhen Lida Tech. Communication Co., Ltd. d/b/a Shijiaet of China; Shenzhen Shibaishi Dianzi Shangwu Co., Ltd. d/b/a Jiayuu and/or YouDaxing of China; Buy Worry-Free Trade Co., Ltd. d/b/a BST Supply I of China; Hong Kong Shihui Technology Co., Ltd. d/b/a Wdingxing of China; Hong Kong Chuanboyao Technology Ltd. d/b/a Mmanage and/or Ffaithful of China; Hong Kong Dora Cross-Border Trading Co., Ltd. d/b/a Doraomi of China; Hong Kong Santaizi Technology Co., Ltd d/b/a STZ Sport of China; Shenzhen Shiyi Gian Maoyi Co., Ltd. d/b/a Classic Innovation of China; and Shenzhen Yanyin Technology Co., Ltd. of China. The complainant requests that the Commission issue a general exclusion order or in the alternative a limited exclusion order, cease and desist orders, and impose a bond upon respondents' alleged infringing articles during the 60-day Presidential review period pursuant to 19 U.S.C. 1337(j).

Proposed respondents, other interested parties, members of the public, and interested government agencies are invited to file comments on any public interest issues raised by the complaint or § 210.8(b) filing. Comments should address whether issuance of the relief specifically requested by the complainant in this investigation would affect the public health and welfare in the United States, competitive conditions in the United States economy, the production of like or directly competitive articles in the United States, or United States consumers.

In particular, the Commission is interested in comments that:

(i) explain how the articles potentially subject to the requested remedial orders are used in the United States;

(ii) identify any public health, safety, or welfare concerns in the United States relating to the requested remedial orders;

(iii) identify like or directly competitive articles that complainant, its licensees, or third parties make in the United States which could replace the subject articles if they were to be excluded;

(iv) indicate whether complainant, complainant's licensees, and/or third party suppliers have the capacity to replace the volume of articles potentially subject to the requested exclusion order and/or a cease and desist order within a commercially reasonable time; and

(v) explain how the requested remedial orders would impact United States consumers.

Written submissions on the public interest must be filed no later than by close of business, eight calendar days after the date of publication of this notice in the **Federal Register**. There will be further opportunities for comment on the public interest after the issuance of any final initial determination in this investigation. Any written submissions on other issues must also be filed by no later than the close of business, eight calendar days after publication of this notice in the **Federal Register**. Complainant may file replies to any written submissions no later than three calendar days after the date on which any initial submissions were due, notwithstanding § 201.14(a) of the Commission's Rules of Practice and Procedure. No other submissions will be accepted, unless requested by the Commission. Any submissions and replies filed in response to this Notice are limited to five (5) pages in length, inclusive of attachments.

Persons filing written submissions must file the original document